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Does Vancomycin Resistance Affect Outcome in Patients With E. faecium Bacteremia?
Garth S Herbert and Louise-Marie Dembry. Section of Infectious Diseases, Department
of Internal Medicine, Yale University School of Medicine, New Haven, CT.

The impact of vancomycin resistance on the outcome of patients with E. faecium
bacteremia has not been definitively established, but it is an important factor in allocating
hospital resources for controlling antibiotic-resistant organisms. This study is a
retrospective analysis comparing the outcome of all patients who developed both
vancomycin-sensitive (VS) and vancomycin-resistant (VR) E. faecium bacteremia at
Yale-New Haven Hospital between 1992 and 2000. All patients with E. faecium
bacteremia were evaluated with respect to risk factors for development of VR E. faecium
bacteremia. Cases (patients with VR E. faecium bacteremia) were then matched to
controls (patients with VS E. faecium bacteremia) on the basis of age, date and unit of
hospitalization, severity of illness, and co-morbidities, including need for dialysis,
immunosuppression, history of organ transplant, HIV status, same-hospitalization
surgery, and presence of a prior oncologic diagnosis. The following factors were
associated with increased risk of developing VR E. faecium bacteremia: exposure to
third-generation cephalosporins (OR 3.69, Cl 1.72-7.89), vancomycin (OR 3.57, Cl 1.627.84), anti-anaerobic agents (OR 2.36, Cl 1.11-5.01), immunosuppressive agents (OR
3.57, Cl 1.62-7.84), hospitalization in an ICU (OR 1.69, C! 0.82-3.51), history of organ
transplant (OR 2.00, Cl 0.74-5.41), and need for dialysis (OR 1.67, Cl 0.70-3.97).
Patients with VR E. faecium bacteremia were more likely to die than patients with E.
faecium bacteremia prior to controlling for severity of illness (64.7% vs. 44.4%, OR 2.29,
Cl 1.10 -4.79). After matching cases to controls on a 1:1 basis to control for severity of
illness and other variables, the difference in mortality rates was no longer statistically
significant (57.1% vs. 45.2%, OR 1.61, C! 0.68-3.82).
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Introduction
The problem of antibiotic resistance is a significant one for the practice of
medicine, and hospitals often devote substantial resources to limiting the proliferation
and spread of antibiotic resistant organisms. Excess costs incurred by hospitals as a
result of infections caused by the six most common antibiotic-resistant nosocomial
infections were estimated to be $1.3 billion/year{in 1992 dollars) by the Office of
Technology Assessment of the US Congress (1). Further, this estimate included only
those expenses encountered in the hospital, and did not encompass costs such as
follow-up care, missed workdays and other related expenditures (1). Organisms such as
methiciilin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant
Pseudomonas aeruginosa are among the most concerning pathogens that require
significant resources to control. In addition, enterococci have emerged as common
nosocomial pathogens in recent years, becoming the second most common cause of
nosocomial urinary tract infections and the third most common cause of nosocomial
bacteremia (2).

While possessing innate resistance to cephalosporins and many other

antibiotics, the Enterococcus genus has only recently been elevated to the level of a
more significant nosocomial pathogen when it developed resistance to vancomycin.
Vancomycin-resistance enterococci (VRE) were first reported in Europe in 1986
(3) . By 1988, isolates of VRE had appeared in the United States, and began
disseminating quickly. Between January of 1989 and March of 1993, the percentage of
VRE isolates reported to the National Nosocomial Infections Surveillance (NN1S) system
increased by a factor of twenty, growing from 0.3% to 7.9% of all enterococcal isolates
(4) . Even more striking, by 1998, more than 20% of all ICU enterococcal isolates
reported to the NNIS were resistant to vancomycin (5). The rapid increase in prevalence
of a multiply resistant organism for which there are few therapeutic options demanded
attention, but it was unclear whether enterococci had actually become more virulent.
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At Yale-New Haven Hospital, recognition of the first strain of vancomycinresistant enterococci occurred in 1992. The number of vancomycin-resistant
enterococcal isolates (the vast majority of which were strains of E. faecium) increased
over the next two years. The spread of resistant organisms prompted the institution of
screening (through rectal or peri-rectal cultures) and subsequent isolation of patients
who were positive for VRE. Beginning in 1994, this screening was directed towards
patients in the medical intensive care unit and those on patient care units with a high
percentage of dialysis and HIV patients, as these units were found to have the highest
prevalence of VRE based on surveillance. In 1998, the population screened for VRE
was expanded to include the oncology unit, based on an increase in VRE colonization
noted via periodic prevalence culture surveys. In spite of these interventions, the
number of patients with VRE bacteremia continued to rise through the end of the
decade.
The experience at YNHH with VRE was very similar to those at hospitals
elsewhere in the country. One of the concerns over this organism’s rapid spread was
the loss of vancomycin as an effective pharmacologic agent for enterococcal infections.
However, clinicians remained (and remain, to this day) divided on the significance of
vancomycin-resistant enterococci, particularly when part of polymicrobial infections.
Enterococci are not considered nearly as pathogenic as S. aureus or P. aeruginosa.
However, there has been concern that VRE could pass vancomycin resistance onto an
organism such as MRSA, thereby eliminating the primary therapeutic option for a
formidable pathogen. While S. aureus with reduced susceptibility to vancomycin were
documented in the U.S. in 1997, it was not through the same mechanism as employed
by enterococci (6). Nonetheless, concerns over the Enterococcus species itself - which
includes organisms that are typically found in the normal flora of our intestine - persist.
But, whether we are justified in devoting significant hospital resources to combat the

3

spread of an organism that is prevalent, but of unknown pathogenicity, is a question that
remains unanswered.

Background
As gram-positive cocci, enterococci were originally classified as Group D
streptococci, and were differentiated from other Streptococcus species by their ability to
grow on 6.5% NaCI. As a whole, enterococci are remarkably hardy, capable of growing
in medium with a pH of 9.6 or containing 40% bile, as well as at temperatures as low as
10°C and as high as 45°C (7). In the 1980s, when it was determined that enterococci
differed from streptococci not only in their ability to grow under harsher conditions but
also genetically, they were reclassified under their own genus (2).
Clinical enterococcal isolates are most commonly determined to be either
Enterococcus faecalis, which comprises roughly 80 - 90% of isolates, or Enterococcus
faecium, comprising an additional 5 - 15% (2). Laboratories differentiate between the
two species based on their differing abilities to ferment sugars. E. faecium is able to
ferment arabinose, while E. faecalis is unable to do so. In addition to the most common
species, approximately 5% of isolates belong to the other species of Enterococcus,
which include E. gallinarum, E. casseliflavus, E. durans, E. avium, and E. raffinosis (2).
These different species of enterococci demonstrate varying mechanisms of antibiotic
resistance. As discussions of the relevance of enterococci are based in no small part on
the organism’s resistance, this subject merits further explanation.

Resistance in enterococci
Just as enterococci have been known to be a causative agent of endocarditis for
decades, certain aspects of its inherent resistance to antibiotics have been known for
decades as well. It was observed in the 1940s that treating endocarditis caused by
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Enterococcus species with penicillin resulted in worse outcomes than streptococcal
endocarditis treated with the same regimen (8). Further investigations since that time
have shown enterococci to be resistant to cephalosporins, anti-staphylococcal
penicillins, aminoglycosides at low-levels, and frequently to fluoroquinolones. It has
been postulated that the emergence of enterococci as nosocomial pathogens is related
to the increasingly frequent use of cephalosporins over the same time period and
consequent selection for enterococci (2).
The mechanisms of antibiotic resistance employed by Enterococcus species are
varied. With regard to penicillin resistance, E. faecalis is known to employ p-lactamases
while E. faecium produces different penicillin-binding proteins (8). Concerning the latter
mechanism, one common penicillin-binding protein (PBP) expressed by E. faecium, PBP
5, demonstrates much lower affinity for penicillin than do other enterococcal PBPs.
Predictably, the loss of the ability to produce PBP 5 by E. faecium has been shown to
dramatically increase penicillin susceptibility in that species (2).
Enterococci also demonstrate varying mechanisms of resistance to
aminoglycosides. In fact, even resistance to gentamicin and streptomycin are mediated
by different mechanisms. Resistance to one is not a certain indication that the organism
will be resistant to the other (2). Resistance to gentamicin, kanamycin, tobramycin, and
amikacin occur through the actions of an acetyltransferase enzyme that inactivates
these aminoglycosides (2). Another enzyme, streptomycin adenyltransferase, mediates
resistance to streptomycin. In addition, moderate-level resistance to all types of
aminoglycosides can occur as a result of low cell-wall permeability (which can be
overcome by concomitant administration of penicillins) (2).
As is the case in its resistance to other antibiotics, enterococcal resistance to
vancomycin can occur in a variety of ways. The five phenotypic types of vancomycin
resistance in enterococci have been designated VanA, VanB, VanC, VanD, and VanE.
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The first two types, VanA and VanB, result from the presence of genes that enterococci
do not possess by nature (2). The first gene, VanA, mediates inducible resistance to
both vancomycin and teicoplanin, another glycopeptide antibiotic (2). Such resistance
can be induced not only by exposure to glycopeptides, but also by antibiotics such as
bacitracin and polymyxin B (2). This gene allows enterococci to produce cell wall
precursors that terminate in D-Ala-D-Lac, instead of the D-Ala-D-Ala sequence that is
bound and inhibited by vancomycin (2). Essential to the resistance mediated by VanA
are two other genes that allow for key steps in mediation of resistance. VanH produces
an enzyme that catalyzes production of D-Lac, which is incorporated into cell-wall
precursors. In addition, VanX produces a peptidase that hydrolyzes D-Ala-D-Ala cell
wall precursors, but has no activity in degrading D-Ala-D-Lac (2). Further, two other
genes, designated VanR and VanS, control expression of the Van H and Van X genes.
The protein-products of these genes increase expression of the VanHAX cluster in the
presence of antibiotics such as vancomycin (2). Of note, this entire gene complex
resides on a transposon in enterococci, thus permitting transmission of the resistance
genes to other bacteria.
The VanB gene mediates resistance to vancomycin, but enterococci expressing
this gene are still susceptible to teicoplanin. The protein produced by this gene also
mediates the production of D-Ala-D-Lac, once again replacing the target of vancomycin
by providing different cell-wall precursors (2). This mechanism of resistance also
requires homologues of VanH, VanX, VanR, and VanS. This system is induced by
vancomycin but not by teicoplanin (2).
Both the VanA and VanB genes can be found on mobile genetic material that can
be transferred from one Enterococcus to another (2). It is precisely this potential for
mobility that allows resistance to be transferred to other enterococci, or possibly to other
similar microbes such as S. aureus. Such transmission has been demonstrated in the
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laboratory, where E. faecalis passed on genes coding for vancomycin resistance to S.
aureus. This transfer was demonstrated both in vitro, on filter paper, and also in vivo,
after strains of the two bacteria were mixed and incubated on the skin of mice (9).
Fortunately, the VanB gene is usually located on the main enterococcal chromosome,
and in this case is not readily transferable. Most likely as a consequence of its ability to
be transmitted from one bacterium to another, VanA is the mode of resistance most
frequently found in the United States (2).
Other variants of vancomycin resistance are far less common. VanC typically
mediates low levels of vancomycin-resistance, and is found in enterococcal species less
frequently observed in the hospital setting (E. gallinarum, E. casseliflavus, E. flavescens)
(2). VanD is a rare mode of resistance observed in E. faecium, and works by a
mechanism similar to VanA and VanB. However, it is found on the main chromosome,
and thus is not transferable (2). Finally, VanE has been documented in E. faecalis, and
resembles resistance mediated by the VanC gene (2).

Related research
Numerous studies have investigated the epidemiology of vancomycin-resistant
enterococci. A complete understanding of the patterns of resistance just described can
allow one to predict some of the findings. For example, since the most common form of
vancomycin resistance is mediated by VanA, the expression of which is increased in the
presence of vancomycin, one can correctly surmise that administration of vancomycin
selects for carriage of VRE. This expectation has been confirmed in several studies (10,
11, 12, 13, 14,15, 16). Furthermore, given that enterococci are inherently resistant to
cephalosporins, administration of cephalosporins (particularly those of the third
generation) is associated with emergence of VRE (10, 11, 12, 14).
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Most studies concerning VRE have shown that greater length of hospitalization
prior to the development of bacteremia, ICU care, and increasing severity of illness are
all risk factors for infection with VRE (12, 14, 17, 18, 19, 20). One study correlated use
of central venous catheters with VRE bacteremia (19). Another found a history of AIDS /
HIV and liver transplant to be highly associated with VRE bacteremia as compared to
VSE bacteremia (11). An association between dialysis and vancomycin-resistant E.
faecium infection or colonization was established in one study (20), while other studies
made a more specific association between hemodialysis and VRE bloodstream
infections (16, 21).
While previous studies cite common factors for the development of VRE
infections, they have not been conclusive in determining whether vancomycin-resistance
independently affects outcome of patients with enterococcal bacteremia. One reason for
this persistent uncertainty is the heterogeneity of published investigations. Studies have
been difficult to compare because investigators have looked at very different patient
populations; some have focused only on ICU patients, others on transplant patients, and
others on the entire hospital population. A focus on different Enterococcus species - E.
faecalis and E. faecium vs. E. faecium alone - also limits direct comparison, as
bacteremia with E. faecium has been associated with worse outcome than bacteremia
with E. faecalis (12, 22). In addition, the use of different control populations (a study by
Edmond used patients without bacteremia (23), while most others used patients with
VSE bacteremia), and varying attempts to correct for the effect of severity of illness on
outcome inhibits direct comparison of available studies.
Among the studies using various populations, enterococcal species, and
matching techniques, some failed to show higher mortality among patients with VRE as
opposed to VSE bacteremia. Mainous et al examined enterococcal bacteremia (both E.
faecium and E. faecalis) in patients in the surgical intensive care unit. The study found
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no difference in mortality between 10 patients with VRE bacteremia and 31 patients with
VSE bacteremia; also, the mortality rate for VRE bacteremia was similar to the mortality
rate for bacteremia due to other organisms (41% vs. 41.7%) (14). Another study
compared 93 patients with VRE bacteremia to 101 patients with VSE bacteremia, the
latter selected because of positive culture dates close to the patients with VRE
bacteremia. The authors found the APACHE II score to be most closely associated with
death; vancomycin-resistance did not have a statistically significant effect on outcome
(19). A third study compared 72 patients with VRE bacteremia to 188 patients with VSE
bacteremia (neither group was limited with regard to enterococcal species). The authors
concluded that vancomycin resistance was more of a marker for severe illness rather
than a predictor of mortality (16).
Among the studies which did find that vancomycin-resistance contributed to
mortality, one was a comparison of 53 cases with VRE bacteremia matched to 53
controls with VSE bacteremia on the basis of severity of illness, age, and hospital unit.
The study included both E. faecium and E. faecalis bacteremia, and found vancomycinresistance to be an independent predictor of mortality (17). In a study performed across
twenty-two institutions, 150 patients with VRE bacteremia were compared to 150
patients with VSE bacteremia. The study examined both E. faecium and E. faecalis, and
demographic data were similar in the two groups. APACHE II scores were used in
multivariate analysis of the data, but comparative APACHE II scores of the two groups
were not reported. Results from this comparison indicated that vancomycin-resistance
was associated with higher mortality, as patients with VRE bacteremia were nearly twice
as likely to die than those with VSE bacteremia (52% vs. 27%, p < 0.05) (11). Finally,
another study matched 27 patients with VRE bacteremia to 27 patients without
bacteremia based on age, underlying illness, and other factors. The study determined
that the bacteremic patients were twice as likely to die as those without bacteremia;
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however, they noted that the mortality rate for their group with VRE bacteremia was
comparable to the rate of those with VSE bacteremia in other studies (23).
Among the studies that exclusively examined E. faecium, the primary cause of
VRE infections, results are similarly mixed as to whether vancomycin-resistance is a
predictor of worse outcome. Garbutt et al. performed a retrospective study of all patients
with E. faecium bacteremia at Barnes-Jewish Hospital in St. Louis over a 28-month
period. The main cohort of patients consisted of 23 patients with VSE and 46 patients
with VRE who all had clinically significant bacteremia (defined as two positive blood
cultures, or one positive blood culture with another site, other than stool, positive for E.
faecium). Severity of illness was evaluated using APACHE II scores, the Organ System
Failure Index, the Chow index (referred to as the Korvick Index in this study - a severity
of illness score established and validated by previous studies of bacteremic patients),
and the Systemic Inflammatory Response Syndrome classification scheme. The authors
concluded that while each of their severity of illness scores was positively associated
with risk of death, vancomycin-resistance was not independently associated with
mortality. However, the authors postulated that a larger sample size might lead to a
different conclusion (24).
Stosor et al. completed a retrospective investigation of patients with E. faecium
bacteremia at Northwestern Memorial Hospital between 1992 and 1995. Medical
records of fifty-three patients were reviewed, of which 32 patients had VSE bacteremia,
and 21 had VRE bacteremia. The authors used the fore-mentioned Chow Index to
control for severity of illness. On statistical analysis, the two groups had similar severity
of illness scores, but the mortality rate differed significantly (76% mortality for patients
with VRE bacteremia, vs. 41% for patients with VSE bacteremia, p = 0.009) (15). This
difference in mortality was attributed to vancomycin-resistance given the otherwise
similar characteristics of the two groups. One shortcoming of this study was the
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inclusion of nine patients with bacteremia that did not meet the author’s own definition of
clinical significance (requiring a minimum of two positive cultures, or one positive culture
with a documented source of infection). As no deaths were attributed to VRE
bacteremia if the bacteremia did not meet the definition of clinical significance (15), this
may have biased the outcome of the study. Moreover, as six of these patients were in
the VSE group and the numbers in each group were very small to start with, the
significance of the outcome of this study is questionable.
A third study examined consecutive patients on a liver transplant service who
developed E. faecium bacteremia. The authors compared 54 patients with VRE
bacteremia to 48 patients with VSE bacteremia, and concluded that vancomycinresistance was an independent predictor of mortality (18). However, the study did not
attempt to control for severity of illness. While all patients were on a liver-transplant
service, examination of the patients’ co-morbidities showed differences between the
numbers of transplant patients in each group (and thus patients who were actively
immunosuppressed), the number of patients who developed bacteremia in the ICU
(patients who were probably more severely ill), and the number of patients who were on
hemodialysis or mechanical ventilation. When these differences are considered, the
group with VRE bacteremia appears to have been more seriously ill than those with VSE
bacteremia.

Current Study
Purpose
As mentioned above, while many studies have examined the effect of
vancomycin-resistance on outcome of patients with bacteremia, there is no general
consensus on whether vancomycin-resistance is an independent predictor of mortality
for these patients. This question demands a carefully structured investigation capable of
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providing a credible answer. Since the majority of vancomycin-resistant enterococci are
E. faecium, we chose to investigate the outcome of bacteremia specifically caused by
this species. Furthermore, as severity of illness undoubtedly has an effect on mortality,
we paid particular attention to this variable. We also tried to avoid a shortcoming of
previous smaller investigations by including a larger number of VRE cases and controls,
electing to investigate a ten-year period at Yale-New Haven Hospital. Determining
whether vancomycin-resistance plays a significant role in the outcome of enterococcal
bacteremia may permit the hospital to appropriately allocate limited resources in
controlling the spread of antibiotic-resistant pathogens.
The hypothesis to be tested is as follows: Vancomycin-resistance does not have
an independent effect on mortality of patients with E. faecium bacteremia after
controlling for severity of illness.

Patients and Methods
The study is a retrospective, case-control analysis of patients with Enterococcus
faecium bacteremia at Yale-New Haven Hospital, a 944-bed university-affiliated, tertiary
care, teaching hospital. Dr. Dembry obtained a list of all patients with enterococcal
bacteremia between July 1992 and October 2002 from the Clinical Microbiology
Laboratory. All patients greater than 2 years of age who had clinically significant
bacteremia were included. Clinically significant bacteremia was defined as positive
blood cultures from two different sites, or one set of positive cultures with another site of
enterococcal infection (urinary tract infection, wound infection, etc.). Rectal swabs and
sputum samples positive for VRE were not considered as sites of infection, and were not
included based on our definition. Bacteremia was classified as either vancomycinsensitive enterococci (VSE) or vancomycin-resistant enterococci (VRE), with the
threshold for defining an organism as resistant to vancomycin set at an MIC > 32 pg/mL.
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In addition, for patients with multiple episodes of bacteremia, only the first instance was
considered in our study.
After examining medical records to determine whether patients met inclusion
criteria (patient age and clinically significant bacteremia), I reviewed the records for the
following: gender and ethnicity; antibiotics received and the duration of treatment, both
before and after the documented bacteremia; co-morbidities, including history of cancer,
HIV, transplant, renal failure requiring dialysis, and same-admission surgery; exposure
to immunosuppressive agents prior to the development of bacteremia; severity of illness
using the Korvick Scale, based on the patient’s condition on the day blood cultures were
drawn; and survival outcome (discharge or death) for that hospitalization.
The Korvick Scale has been validated in prior studies as an effective measure of
severity of illness in patients with bacteremia (25, 26). Point assignments for the criteria
considered by the Korvick Scale are listed in Table 1. Points assigned in each category
are totaled to create the overall severity of illness score, with the possible total score
ranging from 0 to 14 points.

Table 1. Korvick Scale
Mechanical Ventilation

Mental Status

Normal

0

N/A

0

Disoriented

1

Required

2

Stupor

2

Coma

4

Patient Temperature

Cardiac Arrest

< 99.8°F

0

N/A

0

> 99.8°F and < 104°F

1

Present

4

> 104°F

2

Blood Pressure

Unchanged from baseline

0

Systolic drop > 20mm Hg,
diastolic drop > 10mm Hg,
or requiring pressors

2
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While the Korvick Scale measures the patient's severity of illness on the day of
diagnosis of bacteremia, it does not reflect each patient's co-morbid illnesses. However,
since this was a retrospective study and many subjects were hospitalized outside of the
ICU, the thorough documentation that would have made it possible to use other severity
of illness scores (such as the APACHE II scale) was not available.
Culture isolates were determined to belong to Enterococcus species by the
Clinical Microbiology Laboratory based on their ability to grow on 6.5% NaCI and on bileesculin agar. Isolates were further characterized as E. faecium based on their ability to
ferment arabinose. In addition, antimicrobial sensitivity was assessed by disk diffusion
method according to NCCLS guidelines.
Patients were considered to be immunosuppressed if they were actively
receiving chemotherapeutic agents, were on a post-transplant immunosuppressive
regimen, or received an equivalent of at least 20mg per day of prednisone for a
minimum duration of five days, prior to the episode of bacteremia. Also, mortality was
evaluated only in the context of the same hospitalization as the bacteremia. Patients
who were discharged to inpatient hospice (including 4 patients who had VRE
bacteremia, and 2 patients who had VSE bacteremia) were considered to have died
during their hospitalization.
I performed the statistical analysis using EpiCalc 2000, version 1.02. Statistical
significance was assessed using the chi-squared test or Fisher’s exact test for
dichotomous variables and with the Student’s t test for ordinal variables. P values < 0.05
were considered to be statistically significant.
In total, 85 patients were found to have clinically significant vancomycin-resistant
(VR) E. faecium bacteremia between August 1992 and December 2000, and 45 patients
were found to have clinically significant vancomycin-sensitive (VS) E. faecium
bacteremia between August 1992 and October 2002. The time period for identification
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of VS E. faecium bacteremia cases was extended in order to find an adequate number
of controls. (Of note, the treatment of bacteremia with VS E. faecium was unchanged,
so this measure would be unlikely to bias results in any way). Cases were defined as
patients who had clinically significant VR E. faecium bacteremia, and controls were
patients with clinically significant VS E. faecium bacteremia during the aforementioned
periods.
Cases were matched with controls on the basis of severity of illness, age, nursing
unit, date of positive culture, and co-morbidities including need for dialysis, immuno¬
suppression, history of organ transplant, HIV status, same-hospitalization surgery, and
prior oncologic diagnoses. The matching system was similar to techniques used in prior
studies of bacteremia and fungemia (17, 27, 28), and was weighted with the most
important match characteristics being similar severity of illness (SOI) scores, dates of
hospitalization (to ensure comparable treatment), and patient ages. Other
characteristics on which the matching was based included nursing unit and co-morbid
illnesses. Points were allocated to each potential case-control combination in the
following manner: 2 points for an SOI score within 1, and 2 more points for the same
SOI; 2 points for the same gender; 2 for an age within 10 years, with an additional 2
points if the age was within 5 years; 2 points if the patients were hospitalized on the
same nursing unit; 2 points if the date of positive culture was within 2 years, with an
additional point if it was within 12 months; and 2 points for each of the following co¬
morbidities in common: end stage renal disease, HIV status, history of transplant,
surgery during the index hospitalization, a prior oncologic diagnosis, or immuno¬
suppression. Matching of cases to controls (on a 1:1 ratio) was based on the highest
score of at least 14 points. Cases that did not have a score of at least 14 for any casecontrol combination were excluded from the study group, as they were not similar
enough to any controls.
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Of note, while the goal at the outset of the study was to focus on E. faecium
bacteremia to avoid confounding by inter-species differences, we were unsure if there
would be enough controls with VS E. faecium bacteremia. Consequently, we identified
several patients with VS E. faecalis bacteremia that were hospitalized at similar times on
similar nursing units to patients with VR E. faecium bacteremia to serve as potential
controls. Collection of data on these forty patients gave us valuable, firsthand insight
into the differences between enterococcal species, as discussed in the results.
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Results
160 patients with VR E. faecium bacteremia were identified in the report from the
Clinical Microbiology Laboratory. Of these patients, 2 were autopsy specimens, 4 charts
were unavailable, 1 patient was a newborn, and 68 did not have clinically significant
bacteremia, leaving 85 patients for analysis. Of 111 patients with VS E. faecium
bacteremia, 3 were autopsy specimens, 3 charts were unavailable, 4 later had VRE
bacteremia during the same hospitalization (and were thus considered to be cases), 10
were newborns, and 46 did not have clinically significant bacteremia, leaving 45 patients
for analysis.
The 85 patients with VR E. faecium bacteremia and 45 patients with VS E.
faecium bacteremia were analyzed in two separate groups. The main group included all
cases and controls, who by definition had E. faecium bacteremia. The study group
included 42 cases matched on a 1:1 basis with 42 controls. 43 case patients were
unable to be matched with controls due to the relative paucity of patients with
vancomycin-sensitive E. faecium bacteremia, and 3 controls with VSE bacteremia were
not similar enough to any case patients to be matched. In addition, charts for 40
patients with VSE bacteremia secondary to E. faecalis were reviewed (for reasons
described earlier). Statistics from this population are only included in a direct
comparison with the 45 patients with VS E. faecium bacteremia.

VSE Bacteremia - both E. faecium and E. faecalis
Since there were not a large number of patients with VS E. faecium bacteremia,
we considered combining patients with either VS E. faecium or E. faecalis bacteremia as
controls. However, evaluation of the data from 45 patients with VS E. faecium
bacteremia compared to 40 patients with VS E. faecalis bacteremia demonstrated that
this would not be an appropriate comparison. Patients with vancomycin-sensitive
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bacteremia fared far differently based on whether they were infected with E. faecium or
E. faecalis. Although the patients with VSE bacteremia, regardless of species, were
similar in demographic and other characteristics (Table 2), VS E. faecium bacteremia
resulted in higher mortality than VS E. faecalis (OR 3.77, 95% Cl 1.38 - 10.31).

Table 2. Demographics Among Patients with VSE
E. faecium

E. faecalis

Bacteremia

Bacteremia

Number of patients

45

40

Mean age (range)

51.4 (4-89)

60.7 (4-90)

52

68

62.5%

47.5%

White

66.7%

72.5%

African-American

24.4%

20.0%

Hispanic

6.67%

7.5%

2.2%

0%

0 %

0%

2.11

1.98

44.4%

17.5%

P value

Median age
Gender (% male)

OR (95% Cl)

0.038

Race

Other
Unknown
Severity of Illness

0.707

Score (Korvick)
Crude Mortality
3.77 (1.38- 10.31)

Of note, while the Korvick Scores for severity of illness were similar, the average
ages of the two populations (those with different species of VSE) were statistically
different. Each group included two patients under the age of 20, but both the mean and
median age was higher for patients with VS E. faecalis. Also, the mean hospitalization
time prior to bacteremia for the two groups was similar (15.9 ± 19.8 days for E. faecium
vs. 13.5 ± 17.9 days for E. faecalis), suggesting that the number of nosocomial infections
was comparable between the two groups.
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Main Group - All VR and \/S E. faecium
VR E. faecium bacteremia first appeared at Yale-New Haven Hospital in 1992,
and the percentage of E. faecium isolates resistant to vancomycin increased over the
next several years (Fig 1). During the study period, the number of patients with clinically
significant VRE bacteremia, as defined in this study, peaked in 1997.

Fig. 1. E. faecium bacteremia
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Figure 1. The bars depict the number of patients with clinically significant E.
faecium bacteremia (blood cultures drawn from at least two sites, or one positive
blood culture with another site of infection) that occurred each year at Yale-New
Haven Hospital, 1992 - 2000. Patients are divided into those with VRE
bacteremia and those with VSE bacteremia. The line reflects the percentage of
all E. faecium bacteremias that were vancomycin-resistant during each year.

Mortality rates for both VRE and VSE bacteremia did not follow any clear trend
over the study period (Figure 2). This is not surprising for the VSE population, as
vancomycin was available for treatment of such infections during the entire study period.
Pharmacotherapeutic options for VRE bacteremia changed towards the end of the study
period, with the introduction of quinupristin-dalfopristin in September of 1999, and the
approval of linezolid in April of 2000. However, these options were used for only four
study patients, with mixed results. One patient treated with quinupristin-dalfopristin
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survived, while another died of underlying disease after recovering from bacteremia.
One of two patients treated with linezolid survived. Of note, the patient who died after
treatment with linezolid had a severity of illness (Korvick) score of 4, while the other
patient had a score of 2.
Chloramphenicol was the most frequent antibiotic prescribed for patients with
VRE bacteremia over the course of the study, but outcome for these patients was not
significantly different than those treated with other medications (including gentamicin and
doxycyline, as well as linezolid and quinupristin-dalfopristin). The mortality rate for
patients treated with chloramphenicol was 63.9%, while patients treated with other
regimens had a mortality rate of 54.5% (p = 0.304).

Fig 2. Mortality Rate

Figure 2 shows the mortality rate over time for both VRE and VSE bacteremia at
Yale-New Haven Hospital. Statistics were calculated based on all clinically
significant cases of bacteremia.

More than three quarters of the study population had a Korvick Score less than
or equal to 3 (Figure 3). There were relatively few patients at the higher end of the
Korvick scale, particularly in the group with VSE bacteremia. The highest Korvick Score
in each group was 7 points (out of a possible 14 points).
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Fig. 3. Severity of Illness

Figure 3 shows the number of patients observed for each Korvick Score, with
separate totals for those with VRE vs. VSE bacteremia.

The Korvick Scale proved to be an accurate predictor of outcome in this study of
patients with E. faecium bacteremia, particularly those with VRE. The group of patients
with VR E. faecium bacteremia shows a relatively clear trend towards higher mortality
given a higher Korvick Score (Fig. 4). The apparent dip in mortality at a score of 2 may
be a consequence of the fact that only seven patients had a score of 2, providing less
than half the number of observations for a score of 1 (29 patients) or 3 (16 patients).
Also, more than 80% of patients with VR E. faecium bacteremia and a Korvick Score of
at least 5 died; one patient with a score of 6 was the only survivor at this end of the
Korvick Scale.
The trend towards higher mortality with increasing Korvick Score is less definite
in patients with VSE bacteremia. The relatively few patients with both VSE bacteremia
and high Korvick Scores may have precluded us from noting a clearer trend towards
higher mortality in this population.
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Fig 4. Mortality by Severity of Illness

Korvick Score

Figure 4 shows the mortality rate at each severity of illness score. Mortality rates
were calculated for patients with clinically significant VRE or VSE bacteremia.

Among the main group, the demographic data was similar between patients with
VRE bacteremia and those with VSE bacteremia (Table 3). The VRE group was slightly
older than the VSE group, but this difference was not statistically significant. In addition,
the VSE group had a slightly higher percentage of males (64.4% as opposed to 56.5%),
but again, this difference was not statistically significant. Prior to controlling for severity
of illness, patients with VRE bacteremia had a higher crude mortality rate, 64.7% vs.
44.4%. In this analysis, VRE bacteremia was associated with mortality by an odds ratio
of 2.29 (95% Cl 1.10 - 4.79). These two groups also had differing severity of illness
scores, with the average Korvick score being 2.46 in the VRE group, and 2.11 in the
VSE group; however, this difference was not statistically significant (p = 0.314).
The two groups had similar proportions of patients with polymicrobial bacteremia,
32.9% in the VRE group compared to 40.0% in the VSE group. On the other hand, the
percentage of patients in each group with persistent bacteremia (at least one blood
culture drawn on a different day was positive) was much higher in the VRE group 60.0% of patients had persistent VRE bacteremia, while 35.6% of patients had persistent
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VSE bacteremia. The association between VRE and persistent bacteremia was
statistically significant (OR 2.72, 95% Cl 1.29 - 5.75).

Table 3.

Characteristics of Patients with E. faecium Bacteremia
VRE

VSE

Bacteremia

Bacteremia

85

45

55.1

51.4

56.5%

64.4%

White

70.6%

66.7%

African-American

21.2%

24.4%

Hispanic

5.88%

6.67%

Other

1.18%

2.2%

Unknown

1.18%

0%

2.46

2.11

Polymicrobial Bacteremia

32.9%

40.0%

0.76 (0.36- 1.62)

Persistent Bacteremia

60.0%

35.6%

2.72 (1.29-5.75)

Crude Mortality Rate

64.7%

44.4%

2.29 (1.10-4.79)

Number of patients
Age
Gender (% male)

P value

OR (95% C!)

0.250
0.72 (0.34 - 1.51)

Race

Severity of Illness
Score (Korvick)

0.314

As previously mentioned, all patients were considered to have clinically
significant bacteremia in the presence of two positive blood cultures from different sites,
or one positive blood culture with another documented site of infection. Of the patients
with only a single positive blood culture, the additional site of infection varied (Table 4).
Additionally, 28 patients with one positive blood culture for VRE were not considered to
have clinically significant bacteremia although they were documented as being colonized
with VRE by positive rectal swabs. The total number of clinically significant cases of
bacteremia was significantly higher in the VRE group than the VSE group (53.1% vs.
40.5%, p = 0.0414).
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Table 4. Concurrent Sites with VRE
VRE

VSE

160

111

65

28

Urine

8

8

Wound

3

2

Ascites

3

0

Pleural fluid

2

0

CSF

0

1

Bile

3

0

Catheter tip

1

5

Autopsy

0

1

Sputum

3

0

Stool / Rectal swab *

28

0**

Total considered significant

85 (53%)

45 (41%)

P value

Patients with > 1 positive blood
culture during study period
Patients with 2 or more positive blood cultures

0.0086

Patients with only 1 positive blood
culture, and a positive culture from;

0.0414

*These sites were not considered significant sites for purposes of the case definition in patients
with only one blood culture positive for VRE or VSE.
**Rectal swab cultures were reported as either positive or negative for VRE; the Clinical
Microbiology Laboratory did not report the presence of VSE in stool, rectal, or peri-rectal cultures.

Next, several risk factors analyzed in previous studies of enterococcal
bacteremia were reviewed in our patient population. Many of the same trends were
found in our patient population (Table 5). Patients with VRE were more likely to have
been exposed to a minimum of three days of either 3rd generation cephalosporins (OR
4.13, 95% Cl 1.91 - 8.93) or vancomycin (OR 3.57, 95% Cl 1.62 - 7.84) prior to
developing bacteremia. The association between vancomycin and VRE is even more
pronounced when considering all patients who had one or more doses of vancomycin
(OR 5.91,95% Cl 2.67 - 13.09). Also, patients exposed to anti-anaerobic agents (a
minimum of three days of clindamycin or metronidazole) were at a higher risk of
becoming infected with VRE (OR 2.36, 95% Cl 1.11 - 5.01). Finally, exposure to
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fluoroquinolones was associated with a significantly increased risk of infection with VRE;
48.2% of the VRE group received fluoroquinolones prior to developing bacteremia vs.
20.0% of the VSE group (OR 3.73, 95% Cl 1.60 - 8.68).

Table 5. Antibiotic Exposures
VRE

VSE

Bacteremia

Bacteremia

85

45

Cephalosporins (CP)

72.9%

42.2%

3.69 (1.72 -7.89)

3rd Gen. CP

67.1%

35.6%

4.13 (1.91 -8.93)

Vancomycin

56.5%

26.7%

3.57 (1.62-7.84)

Clindamycin or metronidazole

54.1%

33.3%

2.36 (1.11 - 5.01)

Penicillin class

36.5 %

35.6%

1.04 (0.49-2.21)

Aminoglycosides

30.6%

17.8%

2.04 (0.83-4.98)

Fluoroquinolones

48.2%

20.0%

3.73 (1.60-8.68)

Other antibiotics

49.4%

31.1%

2.16 (1.01 -4.63)

OR (95% Cl)
Number of patients
% of patients receiving:

Further analysis of the data yielded additional risk factors for VRE bacteremia
(Table 6). Patients with VRE bacteremia were significantly more likely to have been in
the hospital longer prior to the onset of bacteremia (27.2 days vs. 15.9 days, p =
0.0193). With regard to the total number of days of hospitalization, there was a slight
difference between the two groups, 52.6 days in the VRE group vs. 41.4 days in the VSE
group, however this difference was not statistically significant (p = 0.121). The number
of hospital days after the first positive blood culture for enterococci was identical for the
two groups, 24.6 days for patients with either VSE or VRE bacteremia. However, the
apparent equality in the length of stay after diagnosis of bacteremia is a result of the
number of patients with VRE bacteremia who died shortly after documentation of
positive blood cultures; for survivors, the average number of days in the hospital post
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bacteremia was 31.1 days for the VRE group and 23.0 days for the VSE group. This
difference was not statistically significant (p = 0.245).
In addition, patients on immunosuppressive therapy were found to be at a
statistically significant increased risk for VRE bacteremia (OR 3.57, 95% Cl 1.62 - 7.84).
Hospitalization in one of the intensive care units was associated with VRE bacteremia,
but was not statistically significant (OR 1.69, 95% Cl 0.82 - 3.51). Also, dialysis was
associated with an increased risk of VRE bacteremia, with 29.4% of patients requiring
dialysis prior to the onset of VRE bacteremia vs. 20.0% prior to VSE bacteremia. This
increased risk associated with dialysis was also not statistically significant. Additionally,
there was a non-significant trend for patients with a history of organ transplant to
develop VRE bacteremia (OR 2.00, 95% Cl 0.74 - 5.41). In this study, other co¬
morbidities including HIV status, surgery during the same hospitalization, and an
oncologic diagnosis were not found to be associated with risk for VRE bacteremia.

Table 6.

Risk Factors for VRE Bacteremia
VRE

VSE

P value /

Bacteremia

Bacteremia

OR (95% Cl)

85

45

27.2

15.9

0.0193

52.6

41.4

0.121

ICU stays

55.3%

42.2%

1.69 (0.82 -3.51)

Dialysis

29.4%

20.0%

1.67 (0.70-3.97)

HIV positive

12.9%

13.3%

0.97 (0.33 -2.81)

Transplant

23.5%

13.3%

2.00 (0.74-5.41)

38.8%

42.2%

0.87 (0.42 - 1.81)

Oncologic Diagnosis

35.3%

31.1%

1.21 (0.56-2.61)

Immunosuppression

56.5%

26.7%

3.57 (1.62 -7.84)

Number of patients
Avg days of hospitalization
before bacteremia
Total hospital days

Surgery (this
hospitalization)
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Study Group - Matched Cases and Controls
For the patients with VRE bacteremia who were successfully matched to controls
with VSE bacteremia, the two populations had similar characteristics (Table 7).
Furthermore, after matching on the basis of severity of illness, patient age, date of
hospitalization, and co-morbidities, the mortality rates in the two groups differed
somewhat, but not significantly (57.1% vs. 45.2%, OR 1.61, 95% Cl 0.68 - 3.82). The
average severity of illness score differed slightly between the two groups, but not
significantly. With regard to other factors examined (including ICU status and co¬
morbidities), the two groups did not differ significantly in any category.

Table 7. Demographics, matched group
VRE

VSE

Bacteremia

Bacteremia

42

42

50.3

53.7

28 (66.7%)

27 (64.3%)

White

29 (69.1%)

28 (66.7%)

African-American

11 (26.2%)

10 (23.8%)

Flispanic

1 (2.38%)

3 (7.14%)

Other

1 (2.38%)

1 (2.38%)

ICU stay

20 (47.6%)

16 (38.1%)

1.48 (0.62-3.52)

Dialysis

9(21.4%)

9 (21.4%)

1.00 (0.35-2.84)

HIV positive

8 (19.1%)

6 (14.3%)

1.41 (0.44-4.49)

Transplant

11 (26.2%)

5 (11.9%)

2.63 (0.82 -8.38)

19 (45.2%)

17 (40.5%)

1.21 (0.51 -2.89)

14 (33.3%)

13 (31.0%)

1.12 (0.45-2.79)

1.81

2.00

24 (57.1%)

19 (45.2%)

P value
Number of patients
Age
Gender (% male)

OR (95% Cl)

0.376

Race

Surgery (this
hospitalization)
Oncologic Diagnosis
Severity of Illness
0.595

Score (Korvick)
Crude Mortality Rate

1.61 (0.68-3.82)
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Discussion
This study supports the results of Garbutt et al. who observed that vancomycinresistance does not have a significant effect on outcome of enterococcal bacteremia
after controlling for severity of illness. A long-standing question has been whether
infection with vancomycin-resistant enterococci is merely a marker of severe illness or
actually portends a worse prognosis. Our study suggests the former. The relatively low
pathogenicity of enterococci has never been debated. In fact, prior to the development
of vancomycin resistance, it was debated as to whether enterococcal bacteremia even
merited treatment (29, 30). While it was ultimately determined that patients receiving
appropriate treatment had slightly improved outcomes, this debate underscores the lack
of virulence of enterococci.
The development of vancomycin-resistance renewed the debate over
enterococci again; does VRE lead to higher mortality than VSE? There is currently no
evidence that VRE possesses virulence factors lacking in VSE to suggest differences in
pathogenicity. Furthermore, several studies are concordant in demonstrating that
patients who are more severely ill are more likely to develop infection with VRE (13, 16,
20, 21, 23). Likewise, the present study suggests that patients who develop VRE
bacteremia are more likely to die than those developing VSE bacteremia, but only before
controlling for severity of illness.
it might be postulated that mortality is increased among those with VRE
bacteremia because of a lack of treatment options. This did not appear to be the case in
our study. There were no pan-resistant VRE isolates encountered during review of
susceptibilities, and most of the isolates were sensitive to chloramphenicol. While
patients treated with chloramphenicol did not have better outcomes than patients treated
with other regimens, the higher mortality rate for those patients may represent treatment
bias, as the risks of chloramphenicol may have limited its use to the most severely ill

28

patients. Future studies are not likely to document lack of treatment options as a source
of poorer outcome either, as linezolid and quinupristin-dalfopristin now provide additional
options in the treatment of VRE.
Another interesting finding of our study was that E. faecium was associated with
significantly higher mortality rates than E. faecalis among those patients with
vancomycin-sensitive enterococcal bacteremia. This was in spite of the fact that the
average age of the patients with VS E. faecalis was significantly higher than the patients
with VS E. faecium bacteremia. A difference in virulence between the two species had
been suggested previously. In one study, patients with VS E. faecalis bacteremia were
compared to patients with E. faecium bacteremia, with the latter group containing some
patients infected with VRE (12). The current study population highlights this inequality
between different Enterococcus species, and suggests caution in interpreting results of
earlier studies. Many of these studies grouped both species in the VSE category, while
the VRE group was primarily composed of E. faecium. At Yale-New Haven Hospital,
94.1% of the patients with a blood culture positive for VRE during the study period were
infected with E. faecium, while only 13.1% of the patients with VSE over the same time
period were infected with this enterococcal species. Thus, VRE and VSE categories
largely encompass different species of enterococci. Interpretation of virulence based on
resistance to vancomycin requires cognizance of this fact.
A mechanism accounting for the observed difference in virulence between E.

faecium and E. faecalis has not been described. Both E. faecium and E. faecalis
possess cytolysins (which also act as hemolysins) and aggregation substances (which
facilitate transmission of DNA, including transposons that carry genes mediating
resistance). E. faecalis alone produces virulence factors such as proteases and
hyaluronidase (31). Conversely, there is documentation of an uncharacterized
substance produced only by E. faecium that inhibits phagocytosis in vitro (32). While
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this suggests a possible mechanism for the observed difference in virulence between the
two species, it is clear that the pathophysiology of enterococcal infections is not
completely understood. In any event, such inter-species differences would also suggest
that E. faecium and E. faecalis must be considered separate entities in investigations of
enterococci, as previously suggested by Mackowiak (7).
If the premise is correct that vancomycin-resistance does not affect mortality or
other clinical outcomes, the possibility that VRE is associated with increased cost of care
could be reason alone to pursue aggressive (but cost-efficient) methods of containment.
We did not determine the hospital costs for each patient, but the number of days spent in
the hospital (a major determinant of total costs for hospitalization) was not significantly
different between the VRE and VSE groups. More importantly, while the number of
hospital days prior to bacteremia was significantly longer for the VRE group, the number
of hospital days after documentation of bacteremia was very similar. Studies that
document excess costs for VRE patients (as opposed to their counterparts with VSE)
may be inappropriately attributing increased costs to VRE when it is more likely that the
costs are related to patient’s severity of illness. Stosor et al., for example, reported that
patients with VRE bacteremia were hospitalized significantly longer before developing
bacteremia as compared to those with VSE bacteremia (34.8 days vs. 16.7 days) (15).
However, they attributed all differences in the cost of the hospitalizations to VRE, when
in fact a significant amount of these excess costs were most likely incurred before the
bacteremia.
Of course, factors other than the number of days of hospitalization can affect
costs of treatment. Newer antibiotics used to combat VRE infections will certainly affect
the balance of costs; both linezolid and quinupristin-dalfopristin are far more expensive
than either vancomycin or chloramphenicol. Furthermore, these drugs may be
necessary to treat many infections with VRE that do not involve bacteremia. At Yale-
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New Haven Hospital, bacteremia alone accounts for only 25 - 30% of all VRE infections,
so the number of other infections that may require these expensive drugs is significant.
Clearly, the issue of whether vancomycin-resistance leads to excess costs when treating
enterococcal infections requires further study.
Aside from the possibility that vancomycin-resistance may increase the cost of
treating enterococcal infections, another important reason to continue efforts in
preventing the spread of VRE would be to prevent the spread of resistance to other
organisms. While the transmission of resistance from Enterococcus species to
organisms such as S. aureus had been previously documented both in vitro and in vivo,
it had never been reported to occur outside of a laboratory until very recently. In July,
and again in October of 2002, the CDC reported isolates of S. aureus that were resistant
to vancomycin. The first case involved a dialysis patient, who was documented to have
both VRE and MRSA infections prior to development of vancomycin-resistant
Staphylococcus aureus (VRSA) (33). This patient had also received several courses of
vancomycin therapy. Fewer details were revealed concerning the second patient, but it
is assumed that VRSA developed after conjugation between MRSA and VRE, as this
isolate (like the previous specimen) was documented to possess the VanA phenotype
(34).
If the transmission of vancomycin resistance from Enterococcus species to other
organisms were common, development of VRSA would likely have occurred much
sooner after the appearance of VRE. Furthermore, one would expect that E. faecalis
would quickly become the predominant species of VRE (as it is in VSE) if transmission
of resistance through conjugation happened frequently. The fact that E. faecium
comprises a high percentage of VRE isolates, but only a fraction of VSE isolates
suggests that such transfer probably remains fairly rare. However, even if conjugation
leading to the spread of resistance is rare, the transmission of vancomycin resistance is
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no longer just a laboratory phenomenon, and must be considered in any
recommendations concerning control of VRE. The development of vancomycinresistance in a pathogenic organism such as S. aureus, which can be deadly even in
immunocompetent hosts, eliminates the main therapeutic option for MRSA infections.
Leaving only second-line therapy for such infections would surely lead to increased
mortality due to such infections. For this reason alone, we should continue efforts to
contain VRE, in spite of its low level of virulence. Such efforts can be focused on limiting
risk factors for transmission of VRE that have been established in other studies and
confirmed in this population, and also on general measures that serve to prevent
transmission of all resistant microbes.

Antibiotics

This study confirmed that exposure to certain antibiotics is a risk factor for
infection with VRE. In particular, administration of cephalosporins, especially those of
the third generation, clearly leads to greater risk of VRE infection. It has long been
known that enterococci are intrinsically resistant to cephalosporins, and it is believed that
eliminating the microbial competition by other organisms allows for the proliferation of
enterococci. Furthermore, this study confirmed parenteral vancomycin as a risk factor
for the development of VRE. As mentioned previously, vancomycin and other
glycopeptides are key to the induction of VanA resistance genes, thus selecting for the
growth of enterococci possessing the genes for resistance.
We also found that exposure to antibiotics with activity against anaerobes
(metronidazole and clindamycin) was associated more strongly with VRE than VSE
infection. This association received comment in previous studies (19, 24). The
relationship we observed between exposure to fluoroquinolones and development of
VRE was also noted in a previous study (13). Enterococci are known not only to
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develop, but also to possess innate resistance to fluoroquinolones, so this association is
not surprising. Furthermore, E. faecium has higher minimum inhibitory concentrations
for fluoroquinolones than E. faecalis (MIC90 > 100 pg/mL for the former and M1C90 = 3.12
pg/mL for the latter in one study) (35).
These associations notwithstanding, a direct link between antibiotic exposure
and development of VRE infections has not been proven. Administration of antibiotics to
which enterococci are resistant could plausibly lead to overgrowth of enterococci on the
skin or in bowel. Examination of skin and intestinal carriage of enterococci in patients
with VRE bacteremia showed that 86% of these patients had VRE on their skin, and
100% had positive rectal cultures indicating intestinal carriage (36). VRE carriage on the
skin likely increases the likelihood that an IV catheter would provide a portal of entry into
the bloodstream for VRE. We did not collect data on IV catheter use in our cohort of
patients, but most of them (a significant proportion of whom were in the ICU) likely had
some type of IV catheter. Previous studies have documented an association between
central venous catheters and VRE bacteremia (19, 24).
Another possible mechanism of progression from bacterial overgrowth to
bacteremia could be through passage across the intestinal epithelium. Mice fed an oral
inoculum of E. faecaiis and exposed to antibiotics without activity against enterococci
were shown to develop disseminated infection with E. faecalis, including infection of the
mesenteric lymph nodes, liver, and spleen (37). If the findings in mice can be
extrapolated to humans, enterococci may be capable of translocating across an intact
intestinal mucosa, using the portal venous system as a point of entry into the
bloodstream. In addition, in a study of women undergoing gynecological surgery for
removal of tumors, 46% of lymph nodes cultured yielded Enterococcus species,
demonstrating the potential for translocation across the vaginal epithelium (38).
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Evidence for enterococcal translocation across intact epithelium raises the
possibility that this occurs commonly in humans, but a competent reticuloendothelial
system is capable of eliminating the transient bacteremia. Perhaps administration of
antibiotics leading to enterococcal overgrowth significantly increases the number of
occurrences of bacterial translocation, overwhelming the reticuloendothelial system.
Additionally, the reticuloendothelial system in debilitated hosts may be less efficient at
clearing bacteria from the bloodstream. It is noteworthy that the administration of
immunosuppressive agents, which would also limit the efficacy of the reticuloendothelial
system, was found to be associated with VRE bacteremia in this study. Furthermore,
many patients in this study were on chemotherapeutic regimens; in addition to
suppressing the immune system, mucositis caused by such agents is likely to increase
bacterial translocation, thus predisposing patients to bacteremia in multiple ways.
Regardless of the mechanism linking antibiotic exposure to VRE bacteremia, the
association between the two makes hospital formulary modifications a logical method for
controlling VRE. Noskin et al. reported a significant decrease in the number of VRE
isolates at Northwestern Memorial Hospital after restricting the use of third generation
cephalosporins and encouraging the alternative use of ampicillin / sulbactam or
piperacillin (39). Also, vancomycin has been used for routine surgical prophylaxis or
treatment of infections without documented p-lactam resistance, but many hospitals are
employing stricter controls on its use. Measures include pharmacist review of
vancomycin orders, automatic queries when prescribing vancomycin to ensure the
indication is valid, and automatic stopping of vancomycin orders if criteria for
continuation of therapy are not met (8). Such formulary modifications have been shown
to be effective in controlling outbreaks of VRE even after barrier precautions had failed
to control the outbreak. One report describes limiting vancomycin, clindamycin, and
cefotaxime use, as well as encouraging the substitution of penicillins and p-lactamase
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inhibitors for third generation cephalosporins during an outbreak of VRE. Through these
interventions, the hospital decreased the prevalence of fecal colonization with VRE from
47% to 15 % (p < 0.001) (40).
Additionally, out of concern for the development of infection with VRE, the
Hospital Infection Control Practices Advisory Committee (HICPAC) recommends the use
of metronidazole rather than vancomycin to treat C. difficile colitis. Although antianaerobic antibiotics have been associated with VRE infection (not a significant
association in this study), the risk of vancomycin use leading to VRE infection is felt to
be greater.

Environmental factors
While the effect did not reach statistical significance in our study, time spent in
the ICU is another risk factor for the development of VRE infections. Severity of illness
in the ICU often necessitates use of multiple antibiotics (including the aforementioned
antibiotics that increase risk of infection with VRE), and the need for frequent patient
contact in this setting undoubtedly contributes to the spread of resistant bacteria.
Inadequate hand disinfection between patient encounters is likely to play a role in
transmission of VRE, and routine patient-care items may also serve as vectors for
resistant bacteria. For example, the handle of a thermometer probe in one hospital was
documented to have led to new VRE colonization of several patients. Identification of
the implicated vector was based on genetic analysis of both the patient isolates and the
isolates found on the thermometer (41). To address these potential modes of spread,
HICPAC recommends dedicating patient care items such as stethoscopes, IV poles and
other minor items of equipment, to the rooms of VRE patients.
In addition, alcohol-based hand cleansers may increase compliance with hand
washing, thus helping to limit the spread of VRE. The institution of widely available
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alcohol-based hand gels has improved hand hygiene compliance at Yale-New Haven
Hospital since its introduction in August of 2001. After peaking in 2001, the number of
patients with VRE bacteremia declined considerably in 2002, with only 9 such episodes
documented. The addition of piperacillin / tazobactam to the formulary in September of
2000 (as an alternative to third generation cephalosporins) was the only recent change
in the formulary, and the number of episodes of VRE bacteremia peaked the following
year. Thus, the introduction of alcohol-based hand gels in 2001 probably played a
significant role in the marked decrease in episodes of VRE bacteremia in 2002.
While it did not reach statistical significance in this study, dialysis was associated
with VRE bacteremia (OR 1.92, 95% Cl 0.81 -4.54). An association between VRE and
end-stage renal disease has been made previously (3, 13, 20). Vancomycin is
frequently used to treat line infections caused by Staphylococcus species in dialysis
patients. It has been suggested that renal-dosing of antibiotics (as is required for
vancomycin and gentamicin - two anti-enterococcal agents) may lead to more frequent
sub-therapeutic serum levels than traditional dosing (3). Whether this contributes to
more frequent development of VRE in patients with end-stage renal disease is uncertain.
Other factors associated with dialysis that could be associated with VRE infection could
involve regular exposure to health-care equipment that is used by many different
chronically ill patients. Enterococci, both those resistant to vancomycin and sensitive
isolates, have been shown to persist on cotton, polyester, and plastic surfaces for more
than 90 days (42). This mode of transmission among dialysis patients has not been
documented, but the ability of enterococci to survive on the plastic and polyester - the
same material found in dialysis machines or the furniture (beds, recliners, privacy
curtains) found at dialysis centers - may be significant. Such regular exposure (a
minimum of 3 times every week) to a potentially contaminated environment might
increase VRE colonization if the environment is not adequately cleaned after each
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patient encounter. Careful disinfection of all equipment, as well as dedicated equipment
for patients who are colonized or infected with VRE could be used to limit transmission
of VRE among dialysis patients.

Limitations
There are limitations to the current study. First, while this study was performed
at a major university medical center, encompassing patients from a ten-year period, it is
possible that the study population (including only 45 patients with clinically significant VS
E. faecium bacteremia) was not large enough to detect a difference in outcome between
VRE and VSE bacteremia. In fact, for this difference in mortality of 11.9% to be
statistically significant with a power of 80%, we would have needed a total of 550 cases
and controls. This is a direct consequence of our choice to include only E. faecium
bacteremia. During the study period, there were an additional 8 patients with VRE
bacteremia secondary to E. faecalis, and 685 patients with at least one positive blood
culture for vancomycin-sensitive E. faecalis. However, in analyzing all blood cultures
positive for Enterococcus species, 95% of the bacteremias in the VRE group were
caused by E. faecium, while 85% of the VSE bacteremias were caused by E. faecalis.
As inter-species differences would also affect outcome (confounding the effect of
vancomycin-resistance on mortality), we concluded it was better to include only E.
faecium in the test of our hypothesis. It is possible that only a multi-center study (or one
at a hospital with a much higher prevalence of VRE) would generate sufficient data to
detect a true difference in outcome between VR and VS E. faecium bacteremia, if such a
difference exists.
A second limitation to the current study may be in the use of a non-standardized
measure of severity of illness. The Korvick scale was first used as a measure of degree
of illness in patients with P. aeruginosa bacteremia, and was shown to be predictive of
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outcome (25). It has since been used in studies of bacteremia caused by Enterobacter
species (26) as weil as studies of enterococcal bacteremia (12, 15, 16, 24). While
assessed parameters include mental status, temperature, blood pressure, and the need
for mechanical ventilation, the scale does not encompass other measures of severity of
disease, including co-morbid conditions (such as diabetes, coronary artery disease,
oncologic diagnoses, HIV, etc.), laboratory values, and others. Our study attempted to
account for co-morbid conditions by considering the need for dialysis, HIV status,
requirement for surgery, and a history of organ transplant or cancer as part of the
matching process. Since there was no observable difference between outcome of
patients with VRE and VSE bacteremia after matching cases with controls, it is unlikely
that failure to properly account for severity of illness affected our results.
Another limitation of our study may lie in our definition of clinically significant
bacteremia, requiring a minimum of two positive blood cultures or one positive blood
culture with another documented site of infection. While our aim was to include only
those with true bacteremia in the study, surely we inadvertently excluded patients with
real bacteremia that did not conform to our definition. VRE bacteremia was more likely
to be considered clinically significant than VSE bacteremia (OR 1.66, 95% Cl 1.02 2.71). While this may simply be consistent with our finding that VRE is more likely to
cause persistent bacteremia (and thus more likely to satisfy our definition of clinical
significance), it might also suggest that we excluded more real VSE bacteremias than
VRE bacteremias. One possible way that this could occur is through rapid treatment of
VSE bacteremia. As susceptibility results often take a few days to return from the
laboratory (but a Gram stain can quickly reveal the presence of gram positive
bacteremia), vancomycin is a common empiric treatment for gram-positive bacteremia.
Administration of vancomycin might prevent follow-up cultures from being positive in the
case of VSE bacteremia (and preventing an episode from meeting our criteria of clinical
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significance), but not if the organism is VRE. Another possible explanation for the higher
percentage of clinically significant VRE bacteremia might be that clinicians were more
comfortable in dismissing VSE as a skin contaminant, and forgoing follow-up cultures if
only one set was positive. However, even if these mechanisms affected our study
population, it is our feeling that a single blood culture in a colonized patient may reflect
contamination. True infection is may be difficult to ascertain retrospectively.
Furthermore, the alternative of including all patients with a single positive culture (or
those with positive rectal cultures and a single positive blood culture) could create bias
by adding more patients with pseudo-bacteremia than actual bacteremia.
Finally, the limited numbers of patients in the study precluded a thorough multi¬
variate analysis of risk factors for VRE infection. For example, using univariate analysis,
we found associations between different antibiotics and risk for VRE infection. However,
many patients were on multiple antibiotics, and risk associated with vancomycin use
could also be attributed to cephalosporins if the same patient were receiving multiple
antibiotics. The consequence in such situations where patients received multiple
antibiotics is an overstatement of the risk associated with each individual antibiotic.
Similarly, while length of stay prior to development of bacteremia was associated with
VRE infection, the increased likelihood of exposure to antibiotics during longer hospital
stays could confound this association.

Conclusion
Vancomycin-resistance alone is not associated with increased mortality in
patients with enterococcal bacteremia. However, this does not in itself obviate the
importance of VRE. It has recently been demonstrated in two cases in the United States
that vancomycin resistance can be transmitted from VRE to S. aureus, a much more
serious pathogen. The potential for spread of resistance demands that we continue
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efforts to control proliferation of VRE. Hospital formularies can be monitored more
closely to ensure judicious use of cephalosporins and vancomycin, both of which
contribute to the development of VRE. In addition, efforts to prevent transmission of
VRE to dialysis, transplant, and ICU patients are indicated, as these patients are clearly
at elevated risk for acquiring VRE.
Furthermore, while the difference in pathogenicity between the enterococcal
species has been observed before, it remains uncharacterized and under-recognized.
The exact mechanism of these differences merits further investigation. Clearly, such
inter-species differences in pathogenicity demand consideration in any future studies
regarding the outcome of enterococcal infections.
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